Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium In Tablet Dissolution: Mechanisms, Formulation Strategies, And Performance Optimization

NOV 17, 202667 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose sodium (CCS) is a widely utilized superdisintegrant in pharmaceutical tablet formulations, playing a critical role in accelerating tablet dissolution and drug release. As a cross-linked derivative of carboxymethylcellulose, croscarmellose sodium exhibits rapid swelling and wicking properties that facilitate tablet disintegration in aqueous media, thereby enhancing bioavailability of active pharmaceutical ingredients (APIs). This article examines the molecular mechanisms underlying CCS-mediated dissolution enhancement, formulation design principles, comparative performance against alternative disintegrants, and emerging strategies for optimizing dissolution profiles across diverse therapeutic applications.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Disintegration Mechanisms Of Croscarmellose Sodium

Croscarmellose sodium functions as a superdisintegrant through multiple synergistic mechanisms that distinguish it from conventional disintegrants. At the molecular level, CCS is an internally cross-linked sodium carboxymethylcellulose polymer with a degree of substitution typically ranging from 0.6 to 0.95 carboxymethyl groups per anhydroglucose unit 5. Upon contact with aqueous dissolution media, the carboxylate groups ionize and generate electrostatic repulsion between polymer chains, driving rapid three-dimensional swelling. This volumetric expansion can reach 200–300% of the original particle volume within seconds, creating substantial disruptive forces within the tablet matrix 7.

The disintegration efficacy of croscarmellose sodium derives from three primary mechanisms: swelling, which generates internal pressure to fracture the tablet structure; wicking, wherein capillary action draws dissolution medium into tablet pores and channels; and strain recovery, where compressed polymer particles regain their original configuration upon hydration 5,7. Comparative studies demonstrate that CCS outperforms sodium starch glycolate in wicking capacity, while crospovidone exhibits superior swelling but inferior wicking 5. Notably, the sodium starch glycolate developed a ropy consistency in aqueous slurries that inhibited effectiveness, whereas crospovidone failed to provide adequate API coating for rapid disintegration 5,7.

The particle size distribution of croscarmellose sodium significantly influences dissolution kinetics. Formulations employing CCS with mean particle diameters between 30–50 μm typically achieve faster disintegration than those using 100–150 μm particles, due to increased surface area and more uniform distribution throughout the tablet matrix 13,14,15. However, excessively fine particles (<10 μm) may paradoxically reduce disintegration efficiency by forming a gel layer that impedes water penetration.

Concentration-Dependent Effects On Tablet Dissolution Performance

The concentration of croscarmellose sodium in tablet formulations exhibits a non-linear relationship with dissolution rate, with optimal performance typically observed at 3.5–8% w/w of total tablet weight 13,14,15. In orodispersible domperidone tablets, 7% w/w CCS achieved oral cavity disintegration within approximately 20 seconds, whereas concentrations below 3.5% resulted in disintegration times exceeding 45 seconds 13,14,15. Conversely, CCS concentrations above 10% provided minimal additional benefit and could compromise tablet mechanical strength, increasing friability beyond acceptable limits (>1.0%) 13.

For immediate-release formulations of tamoxifen citrate, the percentage of croscarmellose sodium was optimized such that at least 65% of the API dissolved within 10 minutes in 1000 mL of 0.02N hydrochloric acid at 37°C under 100 rpm stirring 2,3,6. Enhanced formulations achieved ≥70% dissolution within 10 minutes, with superior formulations reaching ≥75–80% release in the same timeframe 2,3,6. These dissolution specifications significantly exceeded the performance of earlier formulations containing only 2% w/w CCS, which exhibited substantially slower release kinetics 2.

In pharmaceutical suspension tablets designed for rapid disintegration, CCS concentrations of 1–6% w/w were employed in combination with 10–50% microcrystalline cellulose and 10–50% of a coprocessed additive (75–95% microcrystalline cellulose with 5–25% calcium-sodium alginate complex) 5,7. These formulations disintegrated within 10–30 seconds in small volumes of water with minimal agitation, forming uniform suspensions suitable for pediatric and geriatric administration 5,7. The CCS was preferably used at 2–15% of the API weight, with optimal results at 5–12% 5,7.

Distribution Strategies: Internal Versus External Phase Incorporation

The spatial distribution of croscarmellose sodium within tablet architecture profoundly impacts dissolution kinetics. Formulations employing a dual-phase distribution strategy—wherein CCS is incorporated both in the granulation (internal phase) and in the final compression mixture (external phase)—consistently demonstrate superior dissolution profiles compared to single-phase incorporation 2,3,6,13,14,15.

In tamoxifen citrate tablets, the formulation comprised an intergranular component containing the API, CCS, a diluent (55–75% w/w), and a secondary disintegrant (5–15% w/w), which was granulated and then blended with an extragranular component containing additional CCS (0–15% w/w), a tertiary disintegrant (5–15% w/w, preferably microcrystalline cellulose), and a lubricant (0.5–1.5% w/w, typically magnesium stearate) 2,3,6. This architecture enabled rapid surface disintegration via external-phase CCS while the internal-phase CCS facilitated core matrix breakdown.

For orodispersible tablets, distributing approximately 50% of total CCS in the internal phase and 50% in the external phase yielded disintegration times of ~20 seconds, whereas 25/75 or 75/25 distributions resulted in disintegration times at least twice as long 13,14,15. This balanced distribution ensures that surface wetting and internal swelling occur simultaneously, maximizing disruptive forces. The internal-phase CCS is typically incorporated during wet granulation, where it is slurried in water (limiting water to only that required for granulation) and mixed with the API and primary excipients 5,7. The brief exposure to water during granulation enhances CCS coating of API particles without excessive solubilization, which would diminish disintegrant efficacy 5,7.

Synergistic Excipient Interactions And Formulation Optimization

Croscarmellose sodium performance is modulated by co-formulated excipients, particularly diluents, secondary disintegrants, and pH modifiers. Mannitol has emerged as the preferred diluent for fast-disintegrating tablets, with optimal particle size distributions between 30–300 μm (mean ~160 μm) and concentrations of 55–70% w/w 13,14,15. Mannitol provides excellent compressibility, minimal hygroscopicity, and a pleasant cooling sensation upon dissolution, while avoiding the excessive disintegration times associated with lactose or sorbitol and the undesirable taste of high-concentration microcrystalline cellulose 13,14,15.

Microcrystalline cellulose (MCC) serves dual roles as a diluent and dry binder, with optimal concentrations of 10–20% w/w in the external phase 13,14,15. MCC concentrations below 10% lead to tablet cleavage and high friability, while concentrations exceeding 20% disturb powder flow and compression characteristics on conventional tablet presses 13,14,15. In pharmaceutical suspension tablets, MCC at 10–50% w/w combined with a coprocessed MCC-calcium alginate complex (10–50% w/w) provided structural integrity while maintaining rapid disintegration 5,7.

The incorporation of alkaline agents can dramatically alter CCS-mediated dissolution, particularly for sustained-release applications. Formulations combining CCS with sodium bicarbonate or other alkali metal salts (sodium or potassium salts) and magnesium oxide as an alkali agent achieved controlled, gradual drug release while resisting disintegration from gastrointestinal peristalsis 1,11. In these systems, the alkaline microenvironment modulates CCS swelling kinetics, transforming a rapid disintegrant into a matrix-forming agent that sustains release over extended periods 1,11. Alternative sustained-release strategies employed CCS with water-soluble polymers (e.g., hydroxypropyl methylcellulose) or hydrophobic bases to further retard dissolution 1,11.

Comparative Performance: Croscarmellose Sodium Versus Alternative Disintegrants

Head-to-head comparisons reveal distinct performance profiles among superdisintegrants. In formulations of 6,7-unsaturated-7-carbamoyl morphinan derivatives, tablets containing croscarmellose sodium achieved >85% dissolution within 15 minutes and >60% within 5 minutes, with minimal formation of degradation products during stability testing 10,12. In contrast, crospovidone-containing tablets, while also achieving >85% dissolution at 15 minutes, exhibited slightly slower initial release (<60% at 5 minutes) and greater susceptibility to degradation 10,12. Sodium starch glycolate formulations demonstrated the poorest performance, with substantially lower dissolution rates and increased impurity formation 10,12.

For verapamil HCl tablets, a synergistic combination of 3–8% w/w natural disintegrant (Ocimum gratissimum seed mucilage powder) with 8–13% w/w croscarmellose sodium provided superior drug release compared to either disintegrant alone 16. This combination leveraged the mucoadhesive and swelling properties of the natural polysaccharide with the rapid wicking and strain recovery of CCS, achieving enhanced bioavailability and pharmacokinetic profiles 16.

In elagolix sodium formulations, the combination of CCS with magnesium oxide as a dispersing agent significantly improved dissolution rates in both acidic (0.1 M HCl, pH 1.2) and neutral (phosphate buffer, pH 6.8) media compared to formulations without dispersing agents or those employing magnesium-aluminum silicate 9. The MgO-CCS system also enhanced storage stability, reducing degradation product formation during long-term storage 9.

Process Parameters And Manufacturing Considerations For Optimal Dissolution

The method of CCS incorporation critically influences final tablet performance. Wet granulation with CCS slurry as the granulating fluid is preferred for APIs requiring uniform distribution and enhanced dissolution 5,7. The CCS is slurried in water at concentrations of 2–15% of the API weight (optimally 5–12%), and this slurry is immediately used to granulate the API and primary excipients 5,7. Limiting water quantity to only that required for granulation and minimizing the time between CCS slurrying and granulation prevents excessive CCS solubilization, which would compromise disintegrant function 5,7. The granulation is then dried (typically in a fluid bed dryer at 40–60°C until moisture content <3%), screened through 1270 μm sieves, and blended with external-phase excipients including additional CCS 2,3,6.

Direct compression is feasible for formulations with favorable powder flow and compressibility, particularly when using spray-dried or co-processed excipients 4. Kampo extract tablets employed direct compression with CCS and sodium bicarbonate, achieving excellent disintegration and dissolution without granulation 4. However, direct compression requires careful attention to powder blending uniformity and may necessitate glidants (e.g., colloidal silicon dioxide at 0.3–0.5% w/w) to ensure consistent tablet weight and content uniformity 2,3,6.

Compression force must be optimized to balance mechanical strength with dissolution performance. Excessive compression (>15 kN for standard 8–10 mm round tablets) can over-densify the tablet matrix, reducing porosity and impeding water penetration, thereby prolonging disintegration time 2,3,6. Conversely, insufficient compression (<5 kN) yields tablets with inadequate hardness (<40 N) and excessive friability (>1.0%), leading to handling and packaging issues 13,14,15. Optimal compression forces typically range from 8–12 kN, producing tablets with hardness of 60–100 N, friability <0.8%, and disintegration times meeting pharmacopeial requirements 2,3,6,13,14,15.

Applications Of Croscarmellose Sodium Across Therapeutic Categories

Immediate-Release Formulations For Oncology And Cardiovascular Therapeutics

Croscarmellose sodium has been extensively employed in immediate-release tablets for tamoxifen citrate, a selective estrogen receptor modulator used in breast cancer treatment 2,3,6. Formulations containing 5–15% w/w tamoxifen citrate with optimized CCS concentrations (typically 2.5–7.5% w/w total, distributed between internal and external phases) achieved ≥75% dissolution within 10 minutes in simulated gastric fluid, significantly enhancing bioavailability compared to earlier formulations 2,3,6. The improved dissolution profile is particularly critical for tamoxifen, as the API exhibits pH-dependent solubility and absorption primarily occurs in the upper gastrointestinal tract 2,3,6.

In verapamil HCl fast-disintegrating tablets (5–10% w/w API), the combination of 3–8% w/w natural disintegrant with 8–13% w/w CCS provided rapid onset of action for acute management of supraventricular arrhythmias and hypertensive episodes 16. Pharmacokinetic studies demonstrated enhanced Cmax and reduced Tmax compared to conventional formulations, translating to faster therapeutic response 16. The formulation maintained stability over 24 months under ICH conditions (25°C/60% RH and 40°C/75% RH), with hardness, friability, and dissolution profiles remaining within specification 16.

Orodispersible And Suspension Tablets For Patient Compliance

Orodispersible tablets containing croscarmellose sodium address the needs of pediatric, geriatric, and dysphagic patient populations who experience difficulty swallowing conventional tablets 13,14,15. Domperidone orodispersible tablets (containing ≤15% w/w API) with 3.5–8% w/w CCS, 55–70% w/w mannitol (30–300 μm particle size), ≥2% w/w maltodextrin, 10–20% w/w microcrystalline cellulose, and 0.5–1.5% w/w magnesium stearate achieved oral cavity disintegration within 20 seconds without water 13,14,15. The rapid disintegration and pleasant organoleptic properties (achieved through 1–5% w/w flavorings and sweeteners) significantly improved patient adherence in antiemetic therapy 13,14,15.

Pharmaceutical suspension tablets designed for extemporaneous suspension preparation employed 1–6% w/w CCS with 10–50% w/w microcrystalline cellulose and 10–50% w/w coprocessed MCC-calcium alginate complex 5,7. These tablets disintegrated within 10–30 seconds in 5–10 mL water with minimal agitation, forming uniform suspensions suitable for dose titration and administration to patients unable to swallow solid dosage forms 5,7. This approach is particularly valuable for pediatric antibiotics, antiretrovirals, and other therapeutics requiring flexible dosing 5,7.

Sustained-Release Systems With Controlled Disintegration Resistance

Paradoxically, croscarmellose sodium can be formulated to achieve sustained release when combined with specific excipients that modulate its swelling behavior 1,11. Formulations containing CCS with alkali metal salts (sodium or potassium salts), magnesium oxide, and optionally water-soluble polymers or hydrophobic bases created matrices resistant to gastrointestinal peristalsis while enabling gradual drug dissolution in the small intestine, duodenum, or colon 1,11. This approach contrasts with conventional CCS applications and demonstrates the versatility of this excipient when formulation parameters are appropriately controlled 1,11.

In these sustained-release systems, the alkaline microenvironment generated by magnesium oxide and alkali metal salts alters CCS ionization and swelling kinetics, transforming the superdisintegrant into a gel-forming matrix 1,11. Drug release is governed by diffusion through the hydrated gel layer and gradual matrix erosion, providing zero-order or

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
ELI LILLY AND COMPANYImmediate-release oncology therapeutics requiring rapid dissolution in upper gastrointestinal tract for breast cancer treatment with pH-dependent absorption.Tamoxifen Citrate TabletsOptimized croscarmellose sodium concentration achieves ≥75% dissolution within 10 minutes in 0.02N HCl at 37°C, significantly enhancing bioavailability through dual-phase distribution strategy.
FMC CORPORATIONPediatric and geriatric patient populations requiring extemporaneous suspension preparation for antibiotics, antiretrovirals, and dose-titrated therapeutics.Pharmaceutical Suspension TabletsTablets disintegrate within 10-30 seconds in minimal water volume using 1-6% croscarmellose sodium with coprocessed MCC-calcium alginate complex, forming uniform suspensions suitable for flexible dosing.
PIERRE FABRE MEDICAMENTAntiemetic therapy for dysphagic, pediatric, and geriatric patients requiring rapid onset without water administration for improved compliance.Domperidone Orodispersible Tablets7% w/w croscarmellose sodium with 55-70% mannitol achieves oral cavity disintegration within 20 seconds without water, maintaining hardness 60-100N and friability <0.8% over 24-month stability.
Shionogi & Co. Ltd.Immediate-release analgesic formulations requiring rapid drug release with enhanced light stability and reduced impurity formation during long-term storage.Morphinan Derivative TabletsCroscarmellose sodium formulations achieve >85% dissolution at 15 minutes and >60% at 5 minutes with minimal degradation products, outperforming crospovidone and sodium starch glycolate in stability testing.
Sandoz AGHormone therapy applications requiring pH-independent dissolution across gastrointestinal pH variations with enhanced storage stability for extended shelf life.Elagolix Sodium TabletsCombination of croscarmellose sodium with magnesium oxide as dispersing agent significantly improves dissolution rates in both acidic (pH 1.2) and neutral (pH 6.8) media while reducing degradation during storage.
Reference
  • Extended release formulation
    PatentInactiveEP3088002A1
    View detail
  • Pharmaceutical formulation
    PatentWO2000064416A2
    View detail
  • Pharmaceutical formulation
    PatentInactiveAU2000043288A1
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png